Pharmacy Week in Review: July 24, 2015

Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.

Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.

Community pharmacies are access points, safe places, and sources of stability when everything else feels uncertain.

In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.

Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.

The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.

Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.

A summer PCAC vote pushes 6 peptide families toward the 503A bulks list—but the FDA's decision is still pending.